TP53 and endometrial cancer: This trial enrolled a population similar to that of PORTEC-3 and GOG-258: non-endometrioid or TP53 mutant stage I and II patients with myometrial invasion, and stage III to IVA endometrial cancer of any histology (Fig. 1).